Weak hands out. Joe’s done a hell of a lot this year on basically no budget. Obviously shares are therefore currency and it hasn’t been overly excessive. Milestones are fueled by money. Yet slow and steady as Generex is now waiting on a response from the FDA which then affords them to submit an IND. Generex has never had all of this licensing funds coming into the company. Love to see how much they’ll accomplish once funded.